Comparing Auryon Atherectomy System with Balloon Angioplasty for treating lower limb blockages

Randomized Controlled Trial of the Auryon Atherectomy System Used in Combination With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects With Critical Limb Ischemia

This study is testing whether using the Auryon Atherectomy System along with balloon angioplasty can help people with lower limb blockages feel better compared to just using balloon angioplasty alone.

Quick facts

• Phase: PHASE4
• Study type: Interventional
• Enrollment: 224 (estimated)
• Sex: All
• Sponsor: Angiodynamics, Inc. (industry)
• Locations: 9 sites (Phoenix, Arizona and 8 other locations)
• Trial ID: NCT06777901 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to evaluate the effectiveness and safety of the Auryon Atherectomy System in conjunction with standard balloon angioplasty compared to balloon angioplasty alone for patients with lower limb blockages due to peripheral arterial disease. The study will enroll up to 1500 subjects who meet specific eligibility criteria, focusing on those with significant stenosis in infra-popliteal arteries. Researchers will assess outcomes such as death, amputation, revascularization, and the improvement of blood flow in the affected limbs. The trial is designed to provide insights into whether the Auryon system offers advantages over traditional angioplasty methods.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older with Rutherford Category classification of 4 or 5 and significant stenosis in a single infra-popliteal artery.

Not a fit: Patients with multiple lesions, those not suitable for angiography, or with a life expectancy of less than one year may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment options for patients with lower limb blockages, potentially reducing the risk of severe complications.

How similar studies have performed: Previous studies have shown promising results with atherectomy systems in treating peripheral arterial disease, suggesting potential for success in this approach.

Eligibility criteria

Inclusion Criteria:

* Age of subject is ≥ 18.
* Estimated life expectancy ≥1 year.
* Subject is able and willing to comply with all assessments in the study.
* Subject has been informed of the nature of the study, agrees to participate, and has signed the approved consent form.
* Rutherford Category classification of 4 or 5 of the target limb.
* Subject is a suitable candidate for angiography and endovascular intervention in the opinion of the investigator or per hospital guidelines.

Angiographic Inclusion Criteria

* Target lesion that is located in a native, de novo infra-popliteal artery (extending from P3 of the popliteal artery to the margin of the ankle mortise).
* Target lesions(s) must be viewed angiographically and have 50-100% stenosis.
* Only a single lesion is included in the study per subject.
* The vessel segment distal to the target lesion must be patent all the way to the ankle, with no significant lesion (≥ 50% stenosis).
* Lesion length ≥50mm and ≤300mm.
* Intraluminal crossing of the lesion. Successful crossing is defined as tip of the guidewire distal to the target lesion in the absence of flow limiting dissections or perforations. If this is not certain, IVUS or OCT may be used to verify this at the operator's discretion.
* Target Lesion reference vessel diameter (RVD) between 1.5mm - 4.5mm by investigator estimate.

Exclusion Criteria:

* Target lesion is in a vessel graft or synthetic graft.
* Treatment of target lesion with radial access.
* Planned target limb major amputation (above-the-ankle).
* Acute limb ischemia or required thrombolysis as a primary treatment modality of the target limb.
* History of prior endovascular or surgical procedure on the index limb within 30 days prior to enrollment or planned within 30 days of the index procedure.
* Subject is pregnant or breastfeeding. (Female subjects of childbearing potential must be non-breastfeeding and have a negative pregnancy test ≤ 7 days before the procedure.)
* Subject has a known coagulopathy or has bleeding diatheses/disorder, thrombocytopenia with platelet count less than 100,000/microliter / less than 80,000K.
* Subject in whom antiplatelet or anticoagulant therapy is contraindicated.
* Subject has known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated.
* Myocardial infarction within 60 days prior to enrollment.
* History of stroke/CVA/TIA within 60 days prior to enrollment.
* History of thrombolytic therapy within 14 days of enrollment.
* Subject has acute or chronic renal disease defined as serum creatinine of \>2.5 mg/dL or \>220 umol/L, or is on dialysis.
* Subject is participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint.
* Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the study requirements and evaluations pre- and post-treatment.
* Subject experiencing ongoing cardiac problems that per the investigator judgment would not make the subject ideal per the procedure.
* Subject has evidence of intracranial or gastrointestinal bleeding within the past 3 months.

Angiographic Exclusion Criteria

* Failure to treat clinically significant inflow lesions in the ipsilateral iliac, femoral, or P1-P2 segments of the popliteal arteries with \<50% residual stenosis with no serious angiographic complications (e.g., embolism or dissection) prior to treatment of the target lesion.
* Residual stenosis, and/or serious angiographic complications (e.g., embolism) prior to the investigational device usage.
* The use of adjunctive devices to treat the target lesion other than the investigative Auryon laser catheter and/or PTA devices, such as scoring balloons, drug-eluting balloons, re-entry devices, lithotripsy devices, or other atherectomy devices (with the exception of bailout stents for Class C/D dissections).

Subjects that do not meet eligibility criteria for the randomized controlled trial are eligible to be enrolled in the observational study.

Observational Study Inclusion Criteria:

* Subjects intended to be treated with the Auryon Atherectomy System for de-novo, restenotic or ISR lesions of the infra-popliteal arteries.
* Subjects presenting with symptomatic PAD with claudication or CLI by Rutherford Category 2 - 6 of the target limb.
* Age of subject is ≥ 18.
* Subject has been informed of the nature of the study, agrees to participate, and has signed the approved study consent form.

Observational Study Exclusion Criteria:

* Subjects with any medical condition that would make him/her an inappropriate candidate for treatment with Auryon Atherectomy System as per Instructions for Use (IFU) or investigator's opinion.
* Subject is pregnant or breastfeeding. (Female subjects of childbearing potential must be non-breastfeeding and have a negative pregnancy test ≤ 7 days before the procedure.)
* Subject is already enrolled in other investigational (interventional) studies that would interfere with study endpoints.

Where this trial is running

Phoenix, Arizona and 8 other locations

• Abrazo Arizona Heart Hospital — Phoenix, Arizona, United States (RECRUITING)
• Kaiser Permanente — San Diego, California, United States (RECRUITING)
• CIS Grey ASC — Gray, Louisiana, United States (RECRUITING)
• MedStar Health Research Institute — Baltimore, Maryland, United States (RECRUITING)
• Massachusetts General Hospital — Boston, Massachusetts, United States (RECRUITING)
• The Washington University — St Louis, Missouri, United States (RECRUITING)
• University of North Carolina Chapel Hill — Chapel Hill, North Carolina, United States (RECRUITING)
• University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States (RECRUITING)
• Prisma Heath-University Medical Group — Greenville, South Carolina, United States (RECRUITING)

Study contacts

• Study coordinator: Anna Quillin

Conditions: Peripheral Arterial Diseases